Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) has received U.S. Food and Drug Administration (FDA) clearance to proceed with Phase 2 clinical development of its lead candidate, Lucid-MS (Lucid-21-302), for the treatment of multiple sclerosis (MS). The approval of the Investigational New Drug (IND) application allows the company to initiate a randomized, double-blind, placebo-controlled study designed to assess the efficacy, safety, and tolerability of the drug in people with MS, using both clinical and radiological endpoints. Trial start-up activities, including site selection, are already underway, with patient enrollment and drug administration expected to commence as soon as possible.
The significance of this milestone lies in Lucid-MS's mechanism of action, which sets it apart from existing MS therapies. Current treatments primarily focus on modulating the immune system to reduce inflammatory attacks on the central nervous system. In contrast, Lucid-MS is designed to provide neuroprotection by inhibiting demyelination—the destruction of the myelin sheath that insulates nerve fibers. It targets protein arginine deiminase 2 (PAD2), an enzyme implicated in myelin degradation. Preclinical models have demonstrated that Lucid-MS can prevent and even reverse myelin breakdown, offering a potential disease-modifying approach that addresses the underlying pathology rather than just the immune response.
The FDA clearance follows a favorable safety profile observed in Phase 1 trials, where Lucid-MS was well tolerated in healthy participants. This progression is a critical step toward bringing a first-in-class therapy to patients who currently face limited options, especially for progressive forms of MS where existing therapies are less effective. As of March 31, 2026, Quantum BioPharma reported over $10 million in cash, digital assets, and liquid investments, positioning the company to fund the upcoming trial and continue its development pipeline.
The announcement underscores the potential of Lucid-MS to transform MS treatment by targeting a novel pathway. If successful in Phase 2, it could pave the way for a new class of neuroprotective agents that not only slow disease progression but also promote repair of damaged myelin. This would represent a paradigm shift in managing a disease that affects millions worldwide, offering hope for improved outcomes and quality of life for patients.
For more information on Quantum BioPharma and its pipeline, visit the company's newsroom at https://ibn.fm/QNTM.
